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This review shows how our microbiome influences health and ultimately how well we age. 
Evidence linking oral bacteria to Alzheimer’s disease (AD) is discussed in the context of aging, 
drawing together data epidemiological, experimental, genetic and environmental studies. 
Immunosenescence results in increased bacterial load as cell-mediated and humoral immune 
responses wane, with the innate immune system contributing to a rise in circulating 
proinflammatory cytokines such as TNFα and IL1β. Aging may favor the proliferation of 
anaerobes in the mouth eliciting a robust TNFα response from the oral epithelium. Maintaining 
the integrity of the blood-brain-barrier (BBB) against a backdrop of increasing bacterial load 
is important and prolonged exposure to high levels of TNFα compromises its integrity. 
Sensitive techniques now detect the “asymptomatic” presence of bacteria in areas previously 
thought to be sterile, providing new insights into the wider distribution of components of the 
microbiome. These “immune-tolerated” bacteria may slowly multiply elsewhere until they 
elicit a chronic inflammatory response; some being considered causal in instances of 
atherosclerosis and back pain. Inflammatory processes,long  associated with AD, have recently 
been further elucidated, in particular revealing the role of the inflammasomes. We propose for 
a subset of AD patients, aging favors the overgrowth of oral anaerobes established earlier in 
life provoking a pro-inflammatory innate response that weakens the BBB allowing bacteria to 
spread and quietly influence the pathogenesis of AD. Finally, we suggest that human 
polymorphisms considered alongside components of the microbiome may provide new 
avenues of research for the prevention and treatment of disease.  
Keywords: Alzheimer’s, oral, microbiome, BBB, innate, immune-tolerated, epidemiological, 
polymorphism, environmental. 
Abbreviations: AD   Alzheimer’s disease, Aβ  amyloid-β, ApoE   apolipoprotein E, BBB   blood-
brain-barrier, EphA1   ephrin type-A receptor 1, GWAS - genome wide association study, IL1β 
interleukin 1- beta, LOAD   late onset Alzheimer’s disease,  LPS   lipopolysaccharide,  NGF   nerve 
growth factor, NLRP1-3 NLR family pyrin domain containing 3, PCR polymerase chain reaction, 
TMAO   trimethylamine-N-oxide, TNFα  tumor necrosis factor alpha, TREM2 triggering receptor on 
myeloid cells 2,  
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INTRODUCTION TO THE MICROBIOME AND DISEASE 
The human ecosystem 
The human body plays host to a plethora of different microscopic organisms ranging in size 
and complexity from viruses and bacteria to multicellular, eukaryotic parasitic worms. 
However, this review will refer solely to the bacterial component of the microbiome. This 
accounts for roughly 1 – 3% of body mass with 10 bacteria for every human cell (NIH Human 
Microbiome Project) and bacterial load is likely to increase with age [1]. Bacteria are found in 
greatest numbers and variety in the mouth, the gut and on the skin.  
Bacteria in the mouth, the gut and on the skin form biofilms. This is a complex ecosystem of 
different species of bacteria forming a symbiotic whole, enabling the attachment and 
proliferation of individuals [2]. Biofilm-forming bacteria release a highly hydrated matrix of 
extracellular polymeric substance, composed of proteins, polyuronic acids, nucleic acids and 
lipids. Together bacteria and this matrix form the bulk components of biofilm [3]. Of the 
estimated 700 oral bacteria identified by DNA, only around 50% have been cultured [4]. Many 
are “unculturable” probably because they cannot survive in isolation, but need other species 
for attachment and/or nutrients [2]. This is a common feature of biofilm “collectives”.  
The alimentary tract is a continuous tube running from the oronasal cavity to the anus. 
Commensal oral and gut bacteria metabolize components of the food we eat and release 
compounds which can be absorbed into the bloodstream. Hence, they contribute, with good 
and bad effect, to the chemicals circulating around our bodies. The bacterial composition of 
the entire tract is also likely to be influenced by diet as many foodstuffs e.g. garlic are 
antibacterial [5] or biofilm disrupters e.g. cranberries [6]. The old adage “you are what you 
eat,” may have particular relevance in this context.  
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Another important feature of the alimentary tract is the immune tolerance afforded to bacteria 
residing in this location [7]. This is a necessary trade-off because immune surveillance must 
ignore foodstuffs to enable the continued survival of the host. However, this does present a 
potential hazard if any of our “commensals” migrate from their normal site of residence. 
Sensitive DNA analysis increasingly reveals that they do, and mounting evidence reveals that 
protective barriers such as the blood brain barrier (BBB) [8-10] and placenta [11] fail to provide 
comprehensive protection. It is also worth noting that when these barriers are breached by sub-
acute levels of “immune-quiet” oronasal or gut bacteria [7, 12] they fail to elicit the discomfort 
associated with diseases such as meningitis or encephalitis [9]. However, outside their 
preferred environment there may be an accumulation due to immunosenescence [13]. The 
microbiome in the context of the aging immune system is discussed below. 
The composition of the microbiome is influenced more by environmental and social factors 
than the host’s genetic background as illustrated by a study of identical twins [14]. This study 
of the salivary microbiome showed that, having shared the same womb and home, monozygotic 
twins began life with very similar microbiomes which diverged as they led more independent 
lives. This is particularly relevant in the context of data for identical twin pairs discordant for 
disease as discussed in the epidemiological data below linking Alzheimer’s disease (AD) to 
oral bacteria.  
EXAMPLES OF THE MICROBIOME LINKED TO DISEASE. 
Atherosclerosis risk and the microbiome. 
Red meat consumption has long been implicated as a risk factor for atherosclerosis even when 
the meat consumed was lean and low in cholesterol. Trimethylamine-N-oxide (TMAO) forms 
part of the cascade to atherosclerotic plaque development and raised levels in blood act as a 
biomarker for atherosclerosis risk [15]. TMAO is produced as a metabolite of L-carnitine and 
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other compounds such as phosphatidylcholine derived from lecithins abundant in red meat. 
Recently a link has been made between red meat/carnitine consumption and certain gut bacteria 
and demonstrates how diet influences the gut microbiome. Vegans and vegetarians produce 
less TMAO than omnivores fed L-carnitine [15]. This suggests that people with a low red meat 
diet have fewer of the specific bacteria required for TMAO production than those eating red 
meat more regularly. Studies in mice have shown that gut bacteria are required to metabolize 
carnitine and lecithin to produce TMAO for the progression of diet-induced atherosclerosis 
[16]. Mice raised in sterile conditions, or given antibiotics and then fed on a diet rich in 
carnitine and lecithin produced significantly less TMAO [15-17]. This provides an example of 
how diet influences the composition of the microbiome and how components of the commensal 
microbiome contribute to developing a disease such as atherosclerosis.  
Specifically, components of the oral microbiome have been implicated in atherosclerosis and 
stroke risk. The oral microbes Aggregatibacter actinomycetemcomitans, a facultative organism 
able to live aerobically or anaerobically and Porphyromonas gingivalis (P. gingivalis), an 
obligate anaerobe, are implicated in atherosclerosis [18]. In the Zaremba et al. study the most 
frequently identified bacteria were P. gingivalis and Treponema denticola [19]. Other 
infectious agents such as Cytomegalovirus and Chlamydophyla pneumoniae are also associated 
with atherosclerosis [20]. Antibiotic treatment for cardiovascular disease has been largely 
unsuccessful, suggesting that a more long-term approach may be required to modify the 
background bacterial load. This is supported by another study showing that prolonged 
periodontal treatment that changed oral hygiene habits, successfully reduced oral anaerobes, 
reduced inflammatory biomarkers and even reversed thickening of the carotid artery intima-




Cancer and the oral microbiome.  
Oral bacteria have long been associated with cancer. A recent prospective study found that the presence 
of serum antibodies to P. gingivalis increased mortality rates in orodigestive tract cancers, even in the 
absence of overt periodontitis [22]. Oral bacteria may be more than simply opportunistic organisms 
taking advantage of a compromised immune system to thrive, but may be actively and adversely 
affecting disease outcome, promoting tumor progression and metastasis. Potential mechanisms are now 
being explored.  Porphyromonas gingivalis has been found in oesophageal squamous cell carcinoma 
(OECC) tissues and identified by immunohistochemistry and quantitative RT-PCR to the 16S rRNA 
gene in 61% of OECC tumours (including 12% of adjacent tissue), but absent from all healthy tissue 
tested, whether from cancer patients (n = 100) or controls (n = 30)  [23].   Another study shows how P. 
gingivalis may promote the invasion of healthy tissue by oral squamous cell carcinoma cells. P. 
gingivalis (but not Fusobacterium nucleatum) induces the expression of proMMP9 by interacting with 
PAR-2 on tumor cells and then processes secreted proMMP9 to the active metalloprotease with its own 
gingipain proteases[24].  Fusobacterium nucleatum has been detected in pancreatic tumors and this is 
also associated with poor prognosis [25].  One mechanism may be linked to immune subversion. 
Fusobacterium nucleatum (from adenocarcinoma) interacts with Natural Killer (NK) immune cells to 
protect tumor cells from attack. The bacterial Fap2 binds to the human inhibitory receptor (TIGIT) on 
immune cells preventing the immune cells’ killer response [26]. Perhaps in the future biopsy samples 
will be more routinely tested for bacteria and this may lead to new treatment regimens.  
 
Low birth weight and preterm babies and the microbiome 
Hormonal changes in pregnancy make women more prone to oral bacterial overgrowth leading 
to increased prevalence of gingivitis and periodontitis [27, 28]. During pregnancy, mothers 
with gum disease are more likely to give birth prematurely or to a low birth weight baby [29-
31]. Not all studies have agreed on the degree of risk to pregnancy afforded by gum disease, 
suggesting that there may be variation between populations [31]. Animal studies have shown 
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that oral bacteria cause low birth weight and prematurity [32, 33]. In most of the cases of human 
pre-term, low birth weight pregnancies examined, oral or gut bacteria were found by culture or 
DNA analysis to have crossed the placental barrier [34]. Growth retardation may result from 
primary effects on fetal development or as a secondary effect by impeding placental blood 
flow. Interestingly, among the bacteria identified that had crossed the placental barrier were 
the oral anaerobes Fusobacterium nucleatum [33] and P. gingivalis [34].  
Type II Diabetes and the microbiome.  
Clinical trials for Type II diabetes targeting oral bacteria show distinct differences between 
populations. In developing countries such as India and Brazil where obesity is less prevalent, 
treatment for periodontitis improved glycaemic control [35, 36]. Similar results were seen in 
Saudi Arabia where glycaemic control improved after periodontal treatment, but only 
significantly in combination with the tetracycline antibiotic doxycycline [37]. However in the 
United States (US) a large trial providing periodontal treatment to Type II diabetic patients 
showed no improvements in glycaemic control [38]. It is perhaps worth noting that the US trial 
did not use systemic antibiotics and no information was available regarding the Body Mass 
Index of patients. It therefore remains possible that in the US population there may be a greater 
contribution to Type II diabetes by bacteria further down the gastrointestinal tract.  
Recent metagenomic approaches showed altered gut microbiota in Type II diabetics [39]. In 
addition to the serological prevalence of bacterial infections [40], evidence for local immune 
responses and occurrence of various bacteria in the affected pancreatic islets was also reported 
[41]. Antigens specific to Helicobacter pylori and Chlamydophyla pneumoniae as well as 
spirochetes were detected in lesion sites and it was suggested that oral and intestinal spirochetes 
may be candidate pathogens for Type II diabetes [41]. 
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Obesity is an established risk factor for Type II diabetes [42] and has long been linked to the 
overgrowth of certain gut bacteria [43]. More recently a study published in Science explored 
the difference between the gut microbiomes of pairs of identical and fraternal human twins 
discordant for obesity. Astonishingly this work revealed that obesity was transmissible [44]. 
Gut bacteria cultured from each twin were fed to mice reared in a sterile environment, with no 
developed microbiome of their own. The mice receiving bacteria from the obese twins (“fat” 
bacteria), developed obesity and those receiving bacteria from the thin twins, (“thin” bacteria) 
remained normal weight, even though all mice were fed the same amount of food. The 
conclusion from these studies was that it is the combination of having a predominantly “thin” 
flora and being fed a healthy diet that is important for maintaining a normal weight. A poor 
diet, lacking fruit and vegetables will likely result in the “thin” bacteria being out-competed by 
any available “fat” bacteria [44].  
EXPLORING THE LINKS BETWEEN ALZHEIMER’S DISEASE AND 
ORAL BACTERIA. 
Background for Alzheimer’s disease 
Dementia affects one in 14 people over 65 years of age and one in six people over 80 years of 
age in the UK. According to UK figures for 2012 published by the Alzheimer’s Society, AD is 
the most common form of dementia accounting for 62% of cases (of the remainder, 17% have 
vascular dementia (VaD), 10% have mixed dementia (AD and VaD), 4% have dementia with 
Lewy bodies, 2% have frontotemporal dementia, 2% have Parkinson's dementia and 3% have 
other dementias). It is possible that the links between the oral microbiome described here apply 
to other forms of dementia but for the purposes of this review we focus on AD as it is the most 
common form.  
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AD symptoms frequently begin with loss of ability to form new memories, eventually leading 
to confusion. Ultimately, inability for self-care often results in institutionalization. There are 
now approximately 500,000 AD sufferers in the UK and 5.4 million in the USA, costing 
approximately £15bn and $183bn respectively per year [45]. Dementia is age-related and in 
Western Europe and the US prevalence (estimated by meta-analysis) in the 85 -89 age range is 
22%, rising to 40 – 50% for the over 90s. There is variation between populations, for example 
figures for Latin America show higher dementia rates of 28% for the 85 – 89 year olds and 
64% for the over 90s . [46] This places a huge burden on society in terms of economics and 
human suffering especially in the context of a burgeoning, aging population. There is currently 
no cure, but it has been calculated that any intervention capable of delaying the symptoms of 
late onset Alzheimer’s disease (LOAD) by even five years, would almost halve the projected 
number of new cases [47]. 
The neuropathological changes associated with AD are similar for familial and sporadic forms 
of the disease. However familial AD results from autosomal dominant mutations in the genes 
encoding either the amyloid-β protein precursor or presenilin proteins which accelerate the 
onset of cognitive decline, often affecting people in their forties or fifties.  AD affects many 
areas in the brain including the hippocampus, frontal, temporal and parietal cortices and the 
cholinergic basal forebrain. The distinctive neuropathological features, amyloid plaques and 
neurofibrillary tangles are found in these areas at much higher density than observed in the 
brains of age-matched cognitively normal subjects. The hippocampus, entorhinal and 
transentorhinal cortices and basal forebrain are particularly vulnerable early in the disease 
trajectory. In these areas neurofibrillary tangles form and amyloid-β (Aβ) peptides are 
deposited as amyloid plaques [48, 49], neurites withdraw and synapses are lost, eventually 
resulting in cell death. The neurotrophins especially nerve growth factor (NGF) and brain 
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derived neurotrophic factor (BDNF) are required here for maintaining cell viability and 
synapse connectivity and the availability of both diminishes as AD progresses [50].    
Neurofibrillary tangles are intracellular fibrillar deposits of hyperphosphorylated tau proteins 
(Figure 1A). Amyloid plaques are extracellular deposits of predominantly fibrillar Aβ peptides 
(Figure 1B). Aβ peptides are derived from cleavage of the amyloid-β protein precursor by the 
enzymes β-secretase and γ-secretase. Cerebrovascular amyloid deposits are found in the small 
blood vessels of the leptomeninges and cortices of around 80% of AD brains.  
Figure 1A shows neurofibrillary tangles comprised of hyperphosphorylated tau. Figure 1B 
shows an amyloid plaque comprised of mostly fibrillar Aβ 
 
The role of Inflammation in Alzheimer’s disease and cognitive decline 
There is evidence of an inflammatory response within the AD brain. Glial cells such as 
astrocytes are recruited to sites of inflammation and once activated, become hypertrophic and 
contribute to the inflammatory processes by releasing pro-inflammatory cytokines such as 
tumor necrosis factor alpha (TNFα) and interleukin 1- beta (IL1β). Inflammasomes are multi-
protein complexes within innate immune cells such as microglia. They are comprised of 
cytoplasmic components including NLRP1-3, NLRC-4, ACS, and caspase-1. Assembly is 
triggered by ligand-mediated toll-like receptor activation or double-stranded RNA dependent 
protein kinase (PKR) activation in innate immune cells including microglia. The net result is 
the production of IL1-beta release in response to e.g. bacterial LPS [51]. P. gingivalis has been 
shown to activate the inflammasome pathway and triggers the release of IL1β via caspase-1 in 
immune cells [52]. The interplay between the inflammasome and autophagy within microglia 
potentially plays a role in the pathogenesis of neurodegenerative diseases. One study has shown 
that inhibiting autophagy with genipin has a knock-on effect of inhibiting downstream 
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inflammasome activation [53]. Further investigations are warranted to determine how Abeta, 
normally cleared via the autophagy route, in its various oligomeric and fibrillar forms, affects 
this interplay.   
Activated astrocytes also produce ApoE which may be involved in Aβ fibrillisation. Over a 
period of months or years the cycle of continued release of pro-inflammatory cytokines and 
amyloidosis exacerbates neuronal damage. It is perhaps worth noting that systemic 
inflammation is also associated with confusion and raised serum levels of Il-6 have been 
implicated in post-operative delirium risk in the elderly [54].   
 
Epidemiological links between oral bacteria and dementia. 
The Swedish Twin Registry [55] was set up in the 1950s and chronicled the life and medical 
histories of twins, including about 20,000 monozygotic pairs born between 1886 and 1967. 
One of the more surprising correlations to emerge from the data for these identical twins was 
that of dementia with tooth-loss in early to mid-life [56]. Of the three potentially modifiable 
risk factors, tooth-loss before age 35, poor education and short adult stature, only tooth loss 
was statistically significant in the identical twins discordant for dementia. Bearing in mind 
identical twins that live apart are unlikely to share the same oral microbiome [14], this 
emphasises a potential link between oral hygiene and dementia risk.  
In accord with this, a twelve year study of North American Nuns reported a similar correlation 
between tooth loss and AD [57]. The cohort comprises of nuns who provide a vast amount of 
medical and personal history and donate their bodies to science for post-mortem study. This 
enables past medical and social history to be correlated with brain pathology. Notably, pre-
existing tooth loss was shown to carry an odds ratio of 2.2 for developing LOAD [57] .  
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Assuming that tooth loss provides a rough indicator for poor oral hygiene this link was further 
corroborated by an eighteen year longitudinal study from the US. Dentate individuals who did 
not brush their teeth daily were reported to have a 22 to 65% greater risk of developing 
dementia compared with those who brushed their teeth three times daily [58]. 
EXPERIMENTAL EVIDENCE LINKING ORAL BACTERIA TO 
ALZHEIMER’S DISEASE. 
Evidence of bacteria found in brains. 
Miklossy’s work in the 1990s highlighted the involvement of several types of spirochetes in 
AD including oral, intestinal or as-yet uncharacterized species, as well the tick-borne Borrelia 
burgdorferi [59, 60]. In 2011 Miklossy published a review indicating that oral bacteria were 
present at ~ 7-fold higher density and far greater variety in AD brains compared to cognitively 
normal controls. Among the AD patients examined, the most prevalent class of bacteria were 
oral spirochetes that are obligate anaerobes [9]. Previously Riviere and colleagues had used 
polymerase chain reaction (PCR) technology and species specific antibodies, to look for oral 
anaerobes (phyla Treponema) in brain samples [10]. PCR identified Treponema in 14 out of 
16 AD brains compared with 4 of 18 controls with more species represented in AD. Treponema 
were also detected using antibodies in 15 out of 16 AD brains compared with 6 of 18 controls 
and there were significantly more AD subjects with cortical Treponemas compared with 
controls [10]. Riviere also examined trigeminal ganglia for bacterial infiltration by PCR. 
Treponema were detected in all subjects, although only samples from AD patients had 
Treponema maltophilum [10]. In order to establish the prevalence of bacteria in brains 
generally (non-AD), Branton and colleagues used deep sequencing with primers designed to 
amplify bacterial 16S ribosomal RNA genes [8]. They found evidence of bacteria across the 
samples tested, 70% of which were α-proteobacteria more normally found in soil and water, 
some of which have now been identified as part of the oral flora [61, 62].  
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Taken together, these findings suggest that certain bacterial phyla, in this case oral anaerobes, 
are more closely associated with AD, since they were not as heavily represented in the non-
AD samples [8-10]. This is consistent with evidence of lipopolysaccharide (LPS) from the oral 
anaerobe P. gingivalis in the brains of AD patients and not controls [63]. 
The link between bacteria and AD-like neurodegeneration has been further illustrated in a 
mouse model.  The AD11 mouse produces antibodies which sequester NGF throughout life, 
steadily removing support for the cholinergic cells of the basal forebrain [64]. The adult AD11 
mouse develops impaired memory function, Aβ and hyperphosphorylated tau lesions, loss of 
cholinergic basal forebrain neurons and hypertrophic ventricles in common with human AD 
[64]. Crucially, when these AD11 mice are raised in sterile conditions the onset of 
neuropathological changes and cognitive deficits is significantly delayed [65].  
Evidence of oral bacteria and TNFα in blood in Alzheimer’s disease 
The association between raised TNFα and AD is well-established and in 2009 researchers in 
the US took blood samples from AD patients and cognitively normal control subjects. They 
used standard Enzymatic Linked ImmunoSorbent Assay (ELISA) techniques with antibodies 
to detect TNFα and looked for serum antibodies for the periodontal bacteria Actinobacillus 
actinomycetemcomitans, Tannerella forsythia and P. gingivalis. Levels of TNFα and 
antibodies for oral bacteria were higher in AD patients compared to controls and the presence 
of serum antibodies for these bacteria carried an odds ratio of 6.1 (p value 0.04) for AD. The 
researchers suggested this could be used as a diagnostic tool [66]. Further to this, one 
longitudinal study has explored the potential for using oral bacteria in blood as a predictive 
tool. This study involved 158 people from the Biologically Resilient Adults in Neurological 
Studies research program at the University of Kentucky who were all cognitively normal at 
baseline. Raised baseline serum antibody levels, specific for the oral anaerobes Fusobacterium 
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nucleatum and Prevotella intermedia, correlated with cognitive deficits in subjects ten years 
later [67].  
Important Implications for Alzheimer’s progression 
Whether oral bacteria themselves or endotoxins (e.g. LPS) released by them gain access to the 
brain, the net result is likely to be microglial activation. Microglial activation is a well-
recognized feature of AD and results in the increased production of proinflammatory cytokines 
such as TNFα and IL1β. This could explain why levels of e.g. TNFα in the cerebrospinal fluid 
of AD patients reach such high levels, 25-fold that of controls [68]. As mentioned, prolonged 
exposure to high concentrations of TNFα weakens the protective BBB making it more 
permeable to ingress of e.g. bacteria or endotoxins [69].  
It is perhaps worth noting that cultured neuronal cells challenged with spirochetes produce Aβ 
[70] and that cultured neuronal (SH-SY5Y) cells exposed to LPS from bacteria, produce 
hyperphosphorylated tau [71]. We know that high concentrations of Aβ, oligomers, or fibrils, 
are neurotoxic. Research shows that Aβ is also toxic to bacteria and Rudolph Tanzi’s 
Alzheimer’s research team now suggest that this response may have evolved as part of the 
brain’s defence against infection [72]. This would certainly help to explain the frequently 
observed amyloid deposition in cognitively normal brains, albeit at lower density. If the 
invading bacteria were susceptible to an Aβ response and the infection was successfully 
cleared, then one might expect some insoluble amyloid plaques to remain as testament to an 
infection successfully resolved. If however AD is caused or worsened by bacteria that provoke, 
but are not killed by, an Aβ response then we might expect both the focus of infection and the 
amyloid deposition to spread. It is also interesting to note that the same stain (congo red) which 
visualises bacterial beta pleated sheet formation (curli fibres on bacteria) is that which stains 
amyloid and it is suggested that it may be that the microglial inflammasome formation 
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produced is due to the inherent recognition of the beta pleated sheet formation of amyloid by 
receptors such as Toll-like receptors as being associated with bacterial invasion [73].  
The genetics linking Alzheimer’s disease to oral hygiene. 
There are several gene polymorphisms that have been associated with increased risk for 
sporadic AD. The ApoE4 polymorphism is most highly correlated with risk of LOAD. Again 
there is some population variation, but in a Norwegian study homozygosity for ApoE4 gave an 
odds ratio of 12.9, compared to 4.2 for ApoE3/E4 heterozygotes [74]. Among the many other 
detrimental effects with which it is associated, ApoE4 compromises the integrity of the BBB 
by activating the cyclophilin A matrix metalloproteinase MMP-9 pathway [75]. If bacterial or 
LPS entry into the brain plays a part in the initiation or progression of AD then maintaining an 
intact BBB is vital.  
All other gene polymorphisms discovered so far, carry a lower individual risk for AD. The 
following section describes four genes associated with AD risk, immune function and bone 
homeostasis: the vitamin D receptor, TNFα, TREM2 and Epha1. The same polymorphism in 
the vitamin D receptor increases both risk of sporadic AD [76] and gum disease (periodontitis) 
[77]. TNFα is involved in immune function, BBB integrity and bone homeostasis. 
Polymorphisms that raise the expression of TNFα increase risk of AD [78] and periodontitis 
[79]. The triggering receptor on myeloid cells (TREM2) is expressed on microglia and is 
involved in immune function and bone homeostasis. A rare mis-sense mutation in the TREM2 
gene (Rs75932628-T) confers risk for AD with an odds ratio of 2.9 in Iceland [80] and a similar 
risk has been reported in a Spanish population [81]. In bone homeostasis TREM2 acts as a co-
stimulator, enhancing osteoclastogenesis which increases the rate of bone resorption [82]. A 
recent study has shown that TREM2 levels are higher in the peripheral blood of AD patients 
and correlate with AD severity [83]. The Ephrin Type-A Receptor 1 (Epha1) gene is one of the 
latest genes associated with AD risk to come out of the genome wide association study 
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(GWAS) [84]. Epha1 is expressed on many cell types including those in the immune system 
and is involved in diverse processes. It is expressed on the vascular endothelium and is 
downregulated shortly after an initial response to bacterial LPS, TNFα and IL1β. In blood 
vessels this is thought to promote immune cell extravasation [85], perhaps relevant to BBB 
integrity in AD. Epha1 has also been implicated in bone homeostasis in a GWAS looking at 
bone geometry and hip fracture risk [86].  
Interestingly, all of these genes share roles in immune function and bone homeostasis, even 
ApoE is involved in bone metabolism although its precise role remains unclear. It is perhaps 
not so surprising that genes that participate in immune function are involved in contributing to 
AD risk. Inflammatory cytokines are associated with AD and these are produced principally 
by the innate immune system. If we speculate that infection may be directly involved in disease 
initiation or progression in a subset of AD cases, it seems reasonable to expect immune 
involvement in risk. That ApoE4, TNFα and perhaps EphA1 also influence BBB integrity is 
particularly important if the penetration of bacteria or LPS into the brain is involved in AD 
pathogenesis in these subjects. An interesting question is whether the shared role in bone 
homeostasis is relevant or merely coincidental. If oral anaerobes are involved in a proportion 
of AD cases, then bone homeostasis may play an active role in influencing the composition of 
the oral flora and hence AD pathogenesis. Figure 2 is a schematic suggesting how factors that 
increase bone resorption at the jaw, are likely to favor the proliferation of anaerobes in the oral 
microbiome and perhaps link tooth loss to AD risk.  
Figure 2. Schematic to illustrate how bone homeostasis could influence the composition of the 
oral microbiome increasing the risk of initiation or progression to AD in a subset of patients. 
Factors promoting bone resorption increase periodontal pocket depth and this shifts the 




Potential dietary influences over the oral/gut microbiome  
Many of the dietary components that have been associated with reducing the risk of AD are 
antibacterial [5, 87-90]. Taken regularly in the diet they would spend time being deposited 
around the mouth throughout life, where they are likely to influence the composition of the oral 
microbiome. Further down the alimentary tract they are also likely to influence the gut flora. 
The Mediterranean diet has long been espoused as helping to prevent AD [91]. This diet is rich 
in foodstuffs with proven antibacterial activity such as garlic [5] and olive oil [87, 88]. Other 
foodstuffs with antibacterial activity such as curcumin [90], and honey [89] are also anecdotally 
purported to provide some protection against AD. Honey has peptides toxic to bacteria e.g. 
bee-defensin1 [92]. Others like cinnamon contain potent antibacterial compounds [93] and also 
disrupt bacterial adhesion [94]. Resveratrol is a natural component of grapes (and found in red wine), 
blueberries, raspberries, and mulberries [95] that has been associated with longevity and is perhaps 
neuroprotective with regard to AD as a dietary component [96]. It is perhaps interesting that like many 
of the moderately protective gene polymorphisms resveratrol is also involved in bone homeostasis and 
immune modulation. One study showed that resveratrol effectively suppressed the loss of jaw bone and 
the release of proinflammatory cytokines in a rat model of periodontitis [97]. Another study showed 
resveratrol reduced P. gingivalis adhesion to endothelial cells of [98]. Many studies [99-102]  have 
described the ability of essential oils and dietary components to disrupt biofilm and this may be a key 
beneficial mechanism of some of these dietary components.  
Perhaps if multiple dietary components, each individually moderately beneficial, are ingested regularly 
they may over time, have subtle effects on the structure and composition of the oral and gut 
biofilms. Indeed recent animal studies found that cinnamon extract added to the chow fed to a 
mouse model of AD, successfully reduced amyloid deposition and reversed cognitive decline 
[103]. Many of these “protective” foodstuffs also have anti-inflammatory properties previously 
thought to be beneficial in countering AD progression. As such, many have been tested for 
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efficacy in clinical trials for AD with disappointing results. It is perhaps worth noting that most, 
if not all, were administered in capsule form, by-passing the mouth entirely. They were 
therefore prevented from behaving as a foodstuff and rendered incapable of directly influencing 
the composition of the oral microbiome.  
Why is the mouth a potential route to Alzheimer’s disease?  
The mouth connects a potentially hostile oral environment directly into bone via teeth, whilst 
at the same time affording immune protection for food and oral bacteria [7]. This must require 
carefully controlled immune surveillance. Immuno-tolerance may be particularly relevant if 
bacteria from the mouth (or gut) escape from their site of origin, allowing them to colonize 
new locations and quietly modulate host cell behavior. Oral epithelial cells produce TNFα in 
response to periodontal bacterial overgrowth and production is enhanced under anaerobic 
conditions [104], inferring that the anaerobes themselves stimulate an enhanced response. The 
capacity to produce TNFα is retained in old age [105]. 
Saliva is crucial in maintaining oral health. It performs many functions; lubricating contact 
between hard and soft surfaces, buffering plaque acids, re-mineralizing tooth surfaces as well 
as modulating the oral biofilm composition. The latter is achieved with the help of secreted 
antimicrobial agents such as immunoglobulins, histatins, peroxidases, lactoferrin and lysozyme 
[106]. Saliva is produced by the parotid, submandibular, sublingual, minor salivary glands and 
Von Ebner glands. The secretions in saliva are produced by mucus cells (sublingual and minor 
glands) or serous acinar cells (parotids) or both (submandibular). Each gland produces a 
secretion with a different composition. Saliva is produced constitutively as unstimulated flow 
or stimulated by the action of chewing [107]. The composition of stimulated and unstimulated 
saliva is not the same because each is composed of different proportions of secretions from the 
various glands and as such has different final constituents and properties. Adequate hydration 
is required for appropriate saliva production and many elderly people become poorly hydrated 
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for many reasons. It is interesting to note that proton pump inhibitors, have been associated 
with increasing the risk for developing AD [108] Omeprazole, among others in its class, also 
suppresses saliva flow [109]. 
Importantly as we age there is a general decrease in the production of unstimulated or 
maintenance saliva and this is further reduced by inactivity [110]. Saliva flow is influenced by 
posture and activity; greatest when standing, slower when sitting and further reduced when 
lying down [110]. Therefore the combined effects of aging, inactivity or infirmity, poor 
hydration and any medications that cause dry mouth, are likely to influence the oral flora and 
promote bacterial overgrowth in the mouth. It is also worth noting that saliva can only penetrate 
the oral biofilm to a certain depth, so its ability to influence biofilm composition is lost as oral 
hygiene deteriorates.  
Potential route of entry for oral bacteria to the brain in Alzheimer’s disease 
Many nerves lead from the oronasal cavity directly to the brain, these include the trigeminal 
and olfactory nerves. The trigeminal nerve has been shown to harbor Treponema [10] and may 
act as a route of entry for oral bacteria into the brain in AD. Another potential route is the 
olfactory nerve, particularly in the context of hyposmia or anosmia as a heralding symptom for 
many neurodegenerative diseases, including AD [111]. The ‘olfactory hypothesis’, suggesting 
the olfactory tract as a potential route of entry for pathogens capable of triggering the 
production of amyloid plaques and neurofibrillary tangles, was first introduced by Mann et al 
in 1988 [112]. Olfactory ensheathing cells (OECs) provide bactericidal protection against 
invasion via the oronasal route. They share many of the capabilities of macrophages; they 
express inducible nitric oxide synthase when challenged, engulf bacteria and migrate [113]. 
However experiments have shown that bacteria such as Staphylococcus aureus, penetrate a 
compromised oronasal mucosa and arrive at the olfactory bulb within six hours, in spite of the 
release of proinflammatory cytokines [114]. OECs have been used successfully to deliver 
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nanoparticles containing drugs to the brain, by-passing the BBB entirely [115]. OECs are able 
to engulf bacteria and migrate towards TNFα released by activated astrocytes [116]. Aged 
macrophages have impaired oxidative burst mechanism [117], if OECs senesce in a similar 
way, they could provide a vehicle for the transport of bacteria that are still alive.  
Figure 3 highlights the similarities between AD disease progression and the route from the 
olfactory nerve to the hippocampus. One of the earliest symptoms in mild cognitive impairment 
that acts as predictor for the progression to AD is impaired olfaction [111, 118] and being 
unaware of this sensory deficit is considered more robustly predictive [119]. A pioneering 
study by Graves and colleagues explored hyposmia as a predictor of progression to AD in a 
normal elderly population of Japanese-Americans [120]. Assessments of 1,604 people were 
made at baseline and again, two years later. Anosmia at baseline carried a 1.92-fold increased 
risk for cognitive decline 2 years later and this risk increased to 4.9-fold if the anosmic person 
also carried at least one ApoE4 allele. This compares with a 1.23-fold risk for cognitive decline 
over the same time-period for normosmic people carrying one ApoE4 allele. The (sex-adjusted) 
risk for anosmic women with ApoE4 in this group carried a remarkable odds ratio of 9.7 
compared to 1.9 with the ApoE4 alone [119, 120]. It may therefore be relevant that the olfactory 
bulb is the first site where neurofibrillary tangles and amyloid deposition is observed in the 
neuropathological trajectory of AD in humans [121] and mouse models of AD [122].  
The next symptom that is often reported is when AD patients misrecognize faces that should 
be familiar [123]. The specific region responsible for facial recognition is the perirhinal cortex. 
A mouse model for AD has shown that Aβ deposits are observed in the perirhinal cortex early 
in the neuropathological trajectory [124]. The perirhinal cortex is connected to the olfactory 
bulb and also the hippocampus, the region responsible for forming new memories. Cell bodies 
in the hippocampus connect to cortical regions and maintenance of these connections is vital 
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for the formation of new memories and cognition. Loss of these connections results in the 
confusion characteristic of AD. 
Figure 3 illustrates the physical connection between the oronasal cavity to the hippocampus 
via the olfactory bulb, entorhinal and perirhinal cortices. The function pertaining to each brain 
region is noted above it and the signs and symptoms experienced by AD patients that also 
corresponds to the order of the appearance of neuropathological changes, are noted 
underneath.   
CONCLUSIONS - FACTORS THAT LINK ORAL BACTERIA TO 
ALZHEIMER’S DISEASE IN THE CONTEXT OF AGING.  
The biggest risk factor for AD is old age, representing a one in four risk for the over eighties 
in Europe [46]. As we get older, bacterial load steadily increases as our humoral and cell-
mediated immune responses wane in favor of the more primitive, but less efficient, innate 
immune system [13]. There is growing evidence that the microbiome composition, species 
identity and combinations, the density and distribution of these bacteria may influence how 
well we age. Gradually, as the innate immunity predominates over time, certain bacteria may 
proliferate and trigger more damaging responses. Against a background of rising bacterial load 
it becomes even more important to maintain the integrity of the BBB. Weakening of the BBB 
either, by any predisposing polymorphisms or as a result of conditions that elicit a sustained 
TNF response, may serve to increase the propensity for bacteria or endotoxins to gain access 
to the brain, trigger neuropathology and alter brain function.  
Many cell types provide innate immune support and are capable of releasing proinflammatory 
cytokines. These include cells in the oral epithelium which release more TNF and IL1β in 
response to the bacteria that thrive as conditions become increasingly anaerobic [104]. Oral 
anaerobiosis is favored in gum disease due to increased periodontal pocket depth and for those 
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wearing dental prostheses, such as dentures or bridges. We know the capacity to produce TNF 
is retained throughout life [105], that levels are increased in inflammatory conditions including 
AD [66, 68] and that increased peripherally circulating TNF weakens the integrity of the BBB 
[69]. Epha1 is one of the new genes from the GWAS associated with AD risk [84] and Epha1-
mediated extravasation of immune cells from blood vessels is induced by TNF [85]. OECs 
are immune cells which may be implicated in helping bacteria to track up nerves into the brain. 
It may therefore be informative to investigate a potential “Trojan horse” role for aging OECs 
under the influence of raised TNF and determine whether EphA1 is involved.   
The mouth is an excellent repository for low grade, chronic infection by bacteria that can 
flourish as the natural production of saliva diminishes with age, inactivity and as a possible 
drug side-effect. Immune tolerated oral bacteria [7] may escape into the circulation, lodge in 
other parts of the body and influence host cell behavior. Genetic polymorphisms that favor jaw 
bone resorption during inflammation will result in increased periodontal pocket depth.  This 
provides the perfect habitat for the proliferation of the oral anaerobes, which are so far most 
closely associated with AD, to thrive. The oral microbiome may be particularly relevant to the 
high risk group identified by Graves and colleagues [120]. The odds ratio of 9.7 for LOAD 
specifically for women, with anosmia, who also carried one or more ApoE4 alleles was 
considered high. If the anosmia they experienced was due to oral anaerobes tracking up the 
olfactory nerve, perhaps the risk of progression to AD was increased if the BBB was also 
weakened by ApoE4. The association between tooth-loss in early to midlife in the twin and 
nun studies suggests oral bacterial overgrowth may be involved in a sub-group of AD patients. 
We know that hormonal fluctuations during the reproductive lifespan [125] and pregnancy 
[126] can exacerbate gum inflammation and induce changes to the oral flora. It is therefore 
possible that hormonal influences have provided conditions for the proliferation of pernicious 
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oral bacteria that contributed to risk in the anosmic, ApoE4 positive women in the Graves 
study.  
Clinical trials for intra-spinal injections of Etanercept (Enbrel), a TNF sequestering antibody, 
have benefited some AD patients [127] and further clinical trials to assess the safety and 
efficacy of Etanercept as a potential therapy are ongoing. However, administration is invasive 
and if TNF is produced in AD to combat infection, effects will likely be short-lived without 
addressing the underlying cause.  
A clinical trial for the systemic antibiotics doxycyline and rifampin in AD patients has reported 
beneficial effects, slowing cognitive decline over 6 months [128]. Further evidence for 
bacterial involvement in AD is reported in a mouse model, as neurodegeneration is delayed 
when the AD11 mice are raised in sterile conditions [65]. These results are encouraging and 
support the hypothesis that infection plays an active role in some cases of AD. The idea that 
infection causes the inflammatory responses in AD is not new, but perhaps it is time to explore 
the possibility of a stealthy, low level infection by a “commensal on the loose”. Furthermore 
this approach may be relevant to other neurodegenerative diseases. The task of modifying the 
oral or gut microbiome, once the reservoir for infection has been identified, will not be trivial. 
The bacterial species responsible are likely to differ between individuals, promoting the need 
for a tailored approach to both screening and treatment. Any intervention will need to provide 
a sustained, monitored reduction of the specific bacteria involved, having identified and 
encouraged the proliferation of beneficial bacteria within the microbiome. Among the (very) 
elderly, more people are likely to have an unhealthy diet and inadequate fluid intake. Further 
study into the effects of poor diet and hydration on the oral and gut flora may therefore be 
warranted in the context of cognitive decline. It may also be worth exploring whether 
influences on the oral microbiome help to explain the failure to translate the effects of some 
drug or dietary components from animal to human trials. If the mouth is a potential site of 
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action, administering compounds in a form that allows prolonged oral retention may be 
beneficial (i.e. not swallowed in capsule form).  
Modifying the oral microbiome will likely involve changing oral hygiene habits to disfavor 
harmful re-colonization. If such interventions prove effective in slowing disease progression, 
they would provide an important route for a Public Health approach to reduce dementia risk in 
an aging population.   
Looking forward, combining human genetic factors with microbiome composition could 
greatly improve our predictive capacity for assessing disease risk. Re-visiting the plethora of 
human genetic polymorphisms, which currently provide only weak indicators of risk, in the 
context of the microbiome may provide more accurate information. Furthermore combining 
these approaches could provide new opportunities for research into the prevention and 
treatment of disease.  
This review was compiled using keyword searches in Google, Pubmed and Web of Science. 
Initial searches lead to subsequent keyword searches as the thread of the literature trail was 
followed down different pathways. Keywords included the following; Alzheimer’s, aging, 
cognitive decline, microbiome, TNF-alpha, Il1-beta, periodontitis, prevalence, gum disease, 
innate immunity, identical twins, discordant, tooth loss, antibacterial properties, oral bacteria, 
blood brain barrier, olfaction, hyposmia, hormone, pregnancy, cycle, atherosclerosis, stroke, 
risk, gut microbiome, diabetes, obesity, low birth weight, pre-term, olfactory ensheathing cells, 
back pain, microglia, neuropathology, amyloid deposition, macrophage, hippocampus, 
perirhinal cortex, vitamin D, vitamin D receptor, TREM2, ApoE4, Epha1, saliva production, 
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Figure 1 Thioflavin S stained temporal slice from the brain of an AD patient. 
                                                                        
 











Figure 3 Relationship between neuropathologically affected regions and signs and symptoms.  
 
